EGFR and glioblastoma: In 2017, Donald M. O’Rourke et al. conducted the first clinical study of human intravenous administration of a single dose of autologous CAR-T cells for the treatment of 10 cases of recurrent glioblastoma (GBM) by retargeting the CAR molecule to EGFR vIII [62].